{
    "nctId": "NCT03771183",
    "briefTitle": "Loreline Study: Characterization of Long Responders Under Eribuline",
    "officialTitle": "National Retrospective Study to Characterize LOng REsponder Under EribuLINE (HALAVEN\u00ae) Metastatic Breast Cancer Patients",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer Patients, Therapy Related Tumor",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 97,
    "primaryOutcomeMeasure": "Measure patient's age at the beginning of Halaven\u00ae treatment in patients who received Halaven\u00ae and who were in response since 6 months or more",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Women aged between 18 and 75 years\n* Metastatic breast cancer patient\n* Patients treated by Halaven\u00ae in second, third or fourth line of treatment for their metastatic breast cancer\n* Halaven\u00ae treatment must have been received between September 2011 and December 2016\n* Patients responding or in stability during at least 6 months under Halaven\u00ae treatment\n* Patients pretreated by at least one line of any other chemotherapy\n* Non opposition form dated and signed by the investigator (attesting that the patient consented orally that clinical, biological and imaging data concerning her were analyzed in this study)\n\nExclusion Criteria:\n\n* Male\n* Patient with cognitive and psychiatric disorders\n* Patient deprived of liberty by judicial or administrative decision\n* Insufficient knowledge or understanding of the French language which does not allow for the non-opposition form to be understood",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}